Literature DB >> 12826049

pp60c-src activation in lung adenocarcinoma.

T Masaki1, K Igarashi, M Tokuda, S Yukimasa, F Han, Y J Jin, J Q Li, H Yoneyama, N Uchida, J Fujita, H Yoshiji, S Watanabe, K Kurokohchi, S Kuriyama.   

Abstract

Nine src family members are known including c-Src, c-Yes, c-Lck, c-Fyn, c-Hck, c-Lyn, c-Blk, c-Fgr and c-Yrk. They encode proteins with molecular weights of 55-62 kilodaltons (kDa), which are either cytoplasmic or membrane-associated protein tyrosine kinases. A close correlation exists between an elevated pp60c-src tyrosine kinase activity and cell transformation. However, the level of activation of pp60c-src in non-small cell lung cancers (NSCLC) remains obscure. The aim of this study was to examine the level of activity of pp60c-src in NSCLC. pp60c-src expression and in vitro protein tyrosine kinase activity in lung cancer tissue samples were measured by western blotting and in vitro kinase assays and compared with those in the surrounding non-tumour lung tissue from the same patient. pp60c-src phosphorylation was assessed by two-dimensional tryptic phosphopeptide mapping. The kinase activity of pp60c-src was significantly activated in NSCLC, especially in adenocarcinomas. In addition, the pp60c-src kinase activity increased with the size of the adenocarcinoma. Two-dimensional tryptic phosphopeptide mapping showed dephosphorylation of pp60c-src at Tyr 530 in adenocarcinomas. The proto-oncogene product, pp60c-src, was activated in NSCLC, especially in adenocarcinomas, in part through the dephosphorylation of Tyr 530. Our results suggest that activation of pp60c-src might play an important role in the progression of lung adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12826049     DOI: 10.1016/s0959-8049(03)00276-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  47 in total

1.  SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.

Authors:  Rui Zheng; Seiji Yano; Yuka Matsumori; Emiko Nakataki; Hiroaki Muguruma; Masanori Yoshizumi; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

Authors:  Jie Zhang; Shailaja Kalyankrishna; Marie Wislez; Nishan Thilaganathan; Babita Saigal; Wei Wei; Long Ma; Ignacio I Wistuba; Faye M Johnson; Jonathan M Kurie
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

Authors:  Julian R Molina; Nathan R Foster; Thanyanan Reungwetwattana; Garth D Nelson; Andrew V Grainger; Preston D Steen; Philip J Stella; Randolph Marks; John Wright; Alex A Adjei
Journal:  Lung Cancer       Date:  2014-05-01       Impact factor: 5.705

4.  Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.

Authors:  Ayca Gucalp; Joseph A Sparano; James Caravelli; Jean Santamauro; Sujata Patil; Alyson Abbruzzi; Christine Pellegrino; Jackie Bromberg; Chau Dang; Maria Theodoulou; Joan Massague; Larry Norton; Clifford Hudis; Tiffany A Traina
Journal:  Clin Breast Cancer       Date:  2011-05-03       Impact factor: 3.225

5.  Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activity.

Authors:  Kyung Mi Lee; Ki Won Lee; Sung Keun Jung; Eun Jung Lee; Yong-Seok Heo; Ann M Bode; Ronald A Lubet; Hyong Joo Lee; Zigang Dong
Journal:  Biochem Pharmacol       Date:  2010-07-01       Impact factor: 5.858

6.  Naringin suppresses the metabolism of A375 cells by inhibiting the phosphorylation of c-Src.

Authors:  Bingyu Guo; Yu Zhang; Qiang Hui; Hongyi Wang; Kai Tao
Journal:  Tumour Biol       Date:  2015-10-17

7.  SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Authors:  Yoshihiro Tokuhisa; Michael E Lidsky; Hiroaki Toshimitsu; Ryan S Turley; Georgia M Beasley; Tomio Ueno; Ketan Sharma; Christina K Augustine; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2013-11-27       Impact factor: 5.344

Review 8.  Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.

Authors:  Byung Min Chung; Eric Tom; Neha Zutshi; Timothy Alan Bielecki; Vimla Band; Hamid Band
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.

Authors:  B Elsberger; R Fullerton; S Zino; F Jordan; T J Mitchell; V G Brunton; E A Mallon; P G Shiels; J Edwards
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

10.  The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants.

Authors:  B M Chung; M Dimri; M George; A L Reddi; G Chen; V Band; H Band
Journal:  Oncogene       Date:  2009-03-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.